ASCO 2019 | Radium-223 label change
Bertrand Tombal
Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium give his opinion on the European Medicines Agency’s (EMA) change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
Related videos
1:26 Comparison of investigator-initiated and industry-initiated trials by Dr Sridhar
Srikala Sridhar
3:25 Enfortumab vedotin as treatment for urothelial carcinomas
Daniel Petrylak
2:53 Issues surrounding patient-centered outcomes in the genitourinary field
John Gore
1:51 The evolving first-line treatment landscape for advanced RCC
Rana McKay
1:10 Key bladder cancer updates from ASCO GU 2019
Brant Inman
